Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.

Roche’s cancer treatment Avastin (bevacizumab) has long been employed as an off-label option for wet age-related macular ...

Outlook Therapeutics, Inc. wins FDA & EU approval for LYTENAVA for wet AMD, but cash burn and competition loom. Click for ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.’s OTLK ONS-5010/LYTENAVA ...

Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibito ...

To study visual and anatomical outcomes of sequenced combined therapy using intravitreal bevacizumab followed by photodynamic therapy (PDT) in eyes with retinal angiomatous proliferation (RAP). Safety ...

Following a request for judicial review by drugmakers Bayer and Novartis, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a statement clarifying that Roche's Avastin ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal bevacizumab may contribute to the need for longer ventilation support and a reduced chance of ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, ...

The U.S. Bevacizumab Biosimilars Market is projected to grow from USD 0.87 Billion in 2025 to USD 2.41 Billion by 2035, while Europe is expected to expand from USD 0.63 Billion to USD 1.61 Billion, ...